Laurence Morin, Louis-Philippe Grenier, Nicolas Foucault, Éric Lévesque, François Fabi, Eve-Lyne Langlais, Alexandra Sebastianelli, Marianne Lavoie, Marc Lalancette, Marie Plante, Mahukpe Narcisse Ulrich Singbo, Vincent Castonguay
{"title":"Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study.","authors":"Laurence Morin, Louis-Philippe Grenier, Nicolas Foucault, Éric Lévesque, François Fabi, Eve-Lyne Langlais, Alexandra Sebastianelli, Marianne Lavoie, Marc Lalancette, Marie Plante, Mahukpe Narcisse Ulrich Singbo, Vincent Castonguay","doi":"10.3390/curroncol31080345","DOIUrl":null,"url":null,"abstract":"<p><p>Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making. The primary objective of this study was to compare the cumulative dose of paclitaxel delivered using 80 mg/m<sup>2</sup>/week, administered using either a 3 weeks out of 4 (WP3) or a 4 weeks out of 4 (WP4) regimen. The secondary objective was to evaluate the clinical outcomes associated with both regimens, including efficacy and toxicity parameters. Our retrospective cohort comprised 149 patients harboring platinum-resistant ovarian cancer treated at the CHU de Québec from January 2012 to January 2023. WP3 and WP4 reached a similar cumulative dose (1353.7 vs. 1404.2 mg/m<sup>2</sup>; <i>p</i> = 0.29). No significant differences in the clinical outcomes were observed. The frequency of dose reduction was significantly higher for WP4 than WP3 (44.7% vs. 4.9%; <i>p</i> < 0.01), mainly due to treatment intolerance from toxicity (34.0% vs. 3.9%; <i>p</i> < 0.01). Our data suggest that a WP3 regimen delivers a similar cumulative dose to WP4, hence offering a better efficacy profile without compromising efficacy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11352914/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31080345","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making. The primary objective of this study was to compare the cumulative dose of paclitaxel delivered using 80 mg/m2/week, administered using either a 3 weeks out of 4 (WP3) or a 4 weeks out of 4 (WP4) regimen. The secondary objective was to evaluate the clinical outcomes associated with both regimens, including efficacy and toxicity parameters. Our retrospective cohort comprised 149 patients harboring platinum-resistant ovarian cancer treated at the CHU de Québec from January 2012 to January 2023. WP3 and WP4 reached a similar cumulative dose (1353.7 vs. 1404.2 mg/m2; p = 0.29). No significant differences in the clinical outcomes were observed. The frequency of dose reduction was significantly higher for WP4 than WP3 (44.7% vs. 4.9%; p < 0.01), mainly due to treatment intolerance from toxicity (34.0% vs. 3.9%; p < 0.01). Our data suggest that a WP3 regimen delivers a similar cumulative dose to WP4, hence offering a better efficacy profile without compromising efficacy.
每周紫杉醇(WP)是治疗铂类耐药卵巢癌患者的化疗基石。临床上已使用多种 WP 给药方案,并对其进行了单独研究。然而,目前还没有对这些方案进行正式比较,从而为临床决策提供客观指导。本研究的主要目的是比较80毫克/平方米/周的紫杉醇累积剂量,采用4周中3周(WP3)或4周中4周(WP4)的给药方案。次要目标是评估两种方案的相关临床结果,包括疗效和毒性参数。我们的回顾性队列包括2012年1月至2023年1月期间在魁北克市立医院接受治疗的149名铂类耐药卵巢癌患者。WP3和WP4的累积剂量相似(1353.7 vs. 1404.2 mg/m2;p = 0.29)。临床结果无明显差异。WP4的剂量减少频率明显高于WP3(44.7% vs. 4.9%; p < 0.01),主要原因是毒性导致的治疗不耐受(34.0% vs. 3.9%; p < 0.01)。我们的数据表明,WP3 方案的累积剂量与 WP4 相似,因此在不影响疗效的情况下,其疗效更好。
期刊介绍:
Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease.
We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.